BRPI0510044A - composição farmacêutica, kit, método para tratar um indivìduo, e, uso de uma primeira e uma segunda quantidade de um ou mais glicocorticóides - Google Patents

composição farmacêutica, kit, método para tratar um indivìduo, e, uso de uma primeira e uma segunda quantidade de um ou mais glicocorticóides

Info

Publication number
BRPI0510044A
BRPI0510044A BRPI0510044-5A BRPI0510044A BRPI0510044A BR PI0510044 A BRPI0510044 A BR PI0510044A BR PI0510044 A BRPI0510044 A BR PI0510044A BR PI0510044 A BRPI0510044 A BR PI0510044A
Authority
BR
Brazil
Prior art keywords
glucocorticoids
pharmaceutical composition
glucocorticoid
individual
treating
Prior art date
Application number
BRPI0510044-5A
Other languages
English (en)
Inventor
Stanko Skrtic
Joergen Johnsson
Hans Lennernos
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Duocort Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duocort Ab filed Critical Duocort Ab
Publication of BRPI0510044A publication Critical patent/BRPI0510044A/pt
Publication of BRPI0510044B1 publication Critical patent/BRPI0510044B1/pt
Publication of BRPI0510044B8 publication Critical patent/BRPI0510044B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, KIT, MéTODO PARA TRATAR UM INDIVìDUO, E, USO DE UMA PRIMEIRA E UMA SEGUNDA QUANTIDADE DE UM OU MAIS GLICOCORTICóIDES. A invenção refere-se a terapia de substituição de glicocorticóide e fornece composições farmacêuticas e kits projetados para suprir um ou mais glicocorticóides a um indivíduo em necessidade deles, de uma maneira que resulte em níveis de soro de glicocorticóide que essencialmente imitam aqueles de um indivíduo saudável, por um período de tempo clinicamente relevante. A composição farmacêutica compreende um ou mais glicocorticóides, em que uma primeira parte de um ou mais glicocorticóides é substancial e imediatamente liberada durante um período prolongado de tempo de pelo menos cerca de 8 horas, e a quantidade do um ou mais glicocorticóides da primeira parte, expressa como equivalentes de hidrocortisona, está em uma faixa de cerca de 15 a cerca de 50% dos equivalentes totais de hidrocortisona. A invenção também refere-se a um método de tratar doenças requerendo tratamento por glicocorticóide, tal como em indivíduos tendo um distúrbio de deficiência de glicocorticóide. Em outro aspecto, a invenção refere-se ao uso de uma primeira e uma segunda quantidade de um ou mais glicocorticóides, para a preparação de uma composição farmacêutica ou kit para o tratamento de um distúrbio de deficiência de glicocorticóide.
BRPI0510044A 2004-04-22 2005-04-21 composição farmacêutica, e, uso de uma composição farmacêutica BRPI0510044B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
SE0401031-0 2004-04-22
US60/564,205 2004-04-22
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (3)

Publication Number Publication Date
BRPI0510044A true BRPI0510044A (pt) 2007-10-16
BRPI0510044B1 BRPI0510044B1 (pt) 2019-01-29
BRPI0510044B8 BRPI0510044B8 (pt) 2021-05-25

Family

ID=35197481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510044A BRPI0510044B8 (pt) 2004-04-22 2005-04-21 composição farmacêutica, e, uso de uma composição farmacêutica

Country Status (25)

Country Link
US (3) US8425937B2 (pt)
EP (2) EP3072507B1 (pt)
JP (2) JP5149618B2 (pt)
CN (2) CN103006592B (pt)
AU (1) AU2005235370B2 (pt)
BR (1) BRPI0510044B8 (pt)
CA (1) CA2564000C (pt)
CY (2) CY1118275T1 (pt)
DK (2) DK1744730T3 (pt)
ES (2) ES2600556T3 (pt)
HR (2) HRP20161380T1 (pt)
HU (2) HUE030546T2 (pt)
IL (2) IL178776A (pt)
LT (2) LT3072507T (pt)
ME (1) ME02584B (pt)
MX (2) MXPA06012011A (pt)
NZ (1) NZ585340A (pt)
PL (2) PL3072507T3 (pt)
PT (2) PT3072507T (pt)
RS (2) RS61501B1 (pt)
SE (1) SE0401031D0 (pt)
SG (1) SG188081A1 (pt)
SI (1) SI3072507T1 (pt)
WO (1) WO2005102271A2 (pt)
ZA (1) ZA200609680B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551336A (en) * 2004-04-22 2010-04-30 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
AU2006322050A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
ME01256B (me) * 2008-07-21 2013-06-20 Dr Falk Pharma Gmbh Farmaceutska formulacija za lečenje gornjeg digestivnog trakta
US20120183610A1 (en) * 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
BR112012029466A2 (pt) 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
MX393493B (es) 2012-11-02 2025-03-21 Murray & Poole Entpr Ltd Tratamiento o prevención de eventos cardiovasculares.
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
HRP20210963T1 (hr) * 2013-04-16 2021-09-17 Murray & Poole Enterprises, Ltd. Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
DK2886108T4 (da) 2013-12-23 2023-01-30 Dr Falk Pharma Gmbh Optimeret farmaceutisk formulering til behandling af inflammatoriske ændringer af øsofagus
US10610534B2 (en) 2015-03-30 2020-04-07 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
WO2026052804A1 (en) 2024-09-06 2026-03-12 Institut National de la Santé et de la Recherche Médicale Hydrocortisone based oral dispersible film and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
NZ278678A (en) 1994-01-31 1998-03-25 Yamanouchi Pharma Co Ltd Compressed moulded tablet with quick disintegration/dissolution in the mouth, mixture of low and high moldable saccharides as carriers
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) * 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
EA008224B1 (ru) 2001-03-13 2007-04-27 Пенвест Фармасьютикалз Ко. Хронотерапевтические дозированные формы
WO2002074316A1 (en) * 2001-03-15 2002-09-26 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
DK1471890T3 (da) * 2002-02-07 2007-01-08 Pharmacia Corp Farmaceutisk doseringsform til mukös afgivelse
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
NZ551336A (en) 2004-04-22 2010-04-30 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
US20120183610A1 (en) * 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
BR112012029466A2 (pt) 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"

Also Published As

Publication number Publication date
EP3072507B1 (en) 2020-12-23
US20140242167A1 (en) 2014-08-28
MX344197B (es) 2016-12-08
EP1744730A2 (en) 2007-01-24
HUE030546T2 (en) 2017-05-29
ME02584B (me) 2017-06-20
JP5149618B2 (ja) 2013-02-20
PL3072507T3 (pl) 2021-07-19
CN103006592A (zh) 2013-04-03
ZA200609680B (en) 2008-08-27
CN1942176A (zh) 2007-04-04
PT1744730T (pt) 2016-10-07
LT1744730T (lt) 2016-10-25
HRP20161380T1 (hr) 2016-12-02
DK1744730T3 (en) 2016-08-29
HK1179525A1 (zh) 2013-10-04
BRPI0510044B1 (pt) 2019-01-29
US20080187586A1 (en) 2008-08-07
CN1942176B (zh) 2013-09-18
RS55198B1 (sr) 2017-01-31
IL178776A (en) 2013-10-31
SG188081A1 (en) 2013-03-28
PL1744730T3 (pl) 2017-01-31
WO2005102271A3 (en) 2006-08-03
US10583146B2 (en) 2020-03-10
LT3072507T (lt) 2021-02-25
MXPA06012011A (es) 2007-04-16
NZ585340A (en) 2012-04-27
CA2564000C (en) 2013-07-02
EP3072507A1 (en) 2016-09-28
RS61501B1 (sr) 2021-03-31
AU2005235370A1 (en) 2005-11-03
IL178776A0 (en) 2007-02-11
CN103006592B (zh) 2016-03-02
CY1124074T1 (el) 2022-03-24
WO2005102271A2 (en) 2005-11-03
JP2007533698A (ja) 2007-11-22
ES2600556T3 (es) 2017-02-09
SI3072507T1 (sl) 2021-04-30
EP1744730B1 (en) 2016-08-03
US20130129823A1 (en) 2013-05-23
HRP20210348T1 (hr) 2021-04-16
US8425937B2 (en) 2013-04-23
HUE053248T2 (hu) 2021-06-28
SE0401031D0 (sv) 2004-04-22
JP5681679B2 (ja) 2015-03-11
IL227375A (en) 2017-08-31
JP2012236846A (ja) 2012-12-06
AU2005235370B2 (en) 2011-06-09
DK3072507T3 (da) 2021-02-08
ES2857600T3 (es) 2021-09-29
CY1118275T1 (el) 2017-06-28
CA2564000A1 (en) 2005-11-03
BRPI0510044B8 (pt) 2021-05-25
PT3072507T (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
BRPI0510044B8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
Olivares-Navarrete et al. Role of non-canonical Wnt signaling in osteoblast maturation on microstructured titanium surfaces
Zhao et al. Mineral trioxide aggregate promotes odontoblastic differentiation via mitogen-activated protein kinase pathway in human dental pulp stem cells
Matarese et al. Transglutaminase 2 up-regulation is associated with RANKL/OPG pathway in cultured HPDL cells and THP-1-differentiated macrophages
Chen et al. Calcium hydroxide–induced proliferation, migration, osteogenic differentiation, and mineralization via the mitogen-activated protein kinase pathway in human dental pulp stem cells
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
Sonoda et al. Exogenous nitric oxide stimulates the odontogenic differentiation of rat dental pulp stem cells
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
Nasi et al. The protective role of the 3-mercaptopyruvate sulfurtransferase (3-MST)-hydrogen sulfide (H2S) pathway against experimental osteoarthritis
Wang et al. Mineral trioxide aggregate enhances the osteogenic capacity of periodontal ligament stem cells via NF‐κB and MAPK signaling pathways
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BRPI0411295A (pt) compostos e seu uso na terapia
BRPI0516105A (pt) composições de fator de crescimento derivado de plaqueta e métodos de uso destas
BRPI0409678A (pt) métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano
de Campos et al. Smoking modulates gene expression of type I collagen, bone sialoprotein, and osteocalcin in human alveolar bone
DE69637556D1 (de) Sulfat-Konjugate der Ursodeoxycholsäure und deren nützliche Verwendung bei entzündlichen Erkrankungen und anderen Anwendungen
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
Krunkosky et al. Effects of TNFα on expression of ICAM-1 in human airway epithelial cells in vitro: oxidant-mediated pathways and transcription factors
Chou et al. Culturing and characterization of human periodontal ligament fibroblasts—a preliminary study
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
Minamikawa et al. Effect of N-acetylcysteine on rat dental pulp cells cultured on mineral trioxide aggregate
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
Canalis et al. 1, 25-Dihydroxyvitamin D3 effects on collagen and DNA synthesis in periosteum and periosteum-free calvaria

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2876 DE 18/02/2026 POR TER SIDO INDEVIDA.